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A B S T R A C T
Glucose transporter type 1 deﬁciency syndrome (GLUT1DS) is the result of impaired glucose transport
into the brain. The ‘‘classic’’ GLUT1DS patient presents with infantile seizures (resistant to traditional
seizure medications), developmental delay, acquired microcephaly, hypotonia, spasticity, and a complex
movement disorder consisting of ataxia and dystonia. However, over the years, other clinical
manifestations have been described, such as paroxysmal exertion-induced dystonia with or without
seizures, choreoathetosis, alternating hemiplegia, and other paroxysmal events, such as intermittent
ataxia, dystonia, and migraine.
At the current state of the art in understanding of GLUT1DS, classifying the disease phenotype as
‘‘classical’’ or ‘‘non-classical’’ seems to be of limited clinical utility. It seems more appropriate to think in
terms of a broad clinical spectrum in which we can observe intellectual impairment, acquired
microcephaly, epilepsy, and movement disorders characterized by different clinical manifestations and
degrees of severity.
Lumbar puncture, a simple investigation, should be considered the ﬁrst diagnostic step that,
moreover, is feasible worldwide. Thereafter, mutational analysis of the solute carrier family 2 (facilitated
glucose transporter) member 1 (SLC2A1) gene should be performed in patients with highly suggestive
clinical ﬁndings and low cerebrospinal ﬂuid glucose (<50 mg/dl or ratio <0.60).
Early diagnosis is critical because it allows prompt initiation of treatment with a ketogenic diet (KD).
Childhood is the critical period for treatment of GLUT1DS: early diagnosis is crucial for an effective
etiological therapy. KD treatment can be useful in adulthood too. Compliance has been found to be much
better in GLUT1DS than in the other conditions for which KD treatment is indicated.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Glucose is the essential substrate for brain energy metabolism.
In the resting state, the adult brain can consume up to 25% of the
body’s total glucose supply,1 while in infants and children it can
use as much as 80%.2
The diffusion of this essential fuel across the blood–brain
barrier is facilitated by glucose transporter type 1 (GLUT1). In the
brain, GLUT1 interacts with other speciﬁc GLUT isoforms mediat-
ing glucose transport into astrocytes and neurons.3
GLUT1 deﬁciency syndrome (GLUT1DS) results from impaired
glucose transport into the brain.4
The classic GLUT1DS patient presents with infantile seizures
(often resistant to traditional seizure medications), developmental
delay, acquired microcephaly, hypotonia, spasticity, and a complex
movement disorder consisting of ataxia and dystonia.5* Corresponding author at: Department of Child Neurology and Psychiatry,
Fondazione IRCCS Istituto Neurologico C. Mondino, Via Mondino, 2 Pavia, Italy.
Tel.: +39 0382 380289; fax: +39 0382380206.
E-mail address: pveggiot@unipv.it (P. Veggiotti).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.07.003Recently the clinical spectrum of GLUT1DS has been broadened
to include developmental delay, epilepsy and/or movement
disorders,6 as well as familial and sporadic paroxysmal exercise-
induced dyskinesia with or without epilepsy.7 There are also
varying degrees of cognitive impairment associated with dysar-
thria, dysﬂuency, and expressive language deﬁcits. In most
patients, the cerebrospinal ﬂuid (CSF)-to-blood glucose ratio is
below 0.50, and CSF lactate is low to normal.
A diagnosis of GLUT1DS can be conﬁrmed by molecular analysis
of the solute carrier family 2 (facilitated glucose transporter)
member 1 (SLC2A1) gene, while analysis of glucose uptake into
erythrocytes can conﬁrm the impaired GLUT1 function. Early
diagnosis is critical because it allows prompt initiation of
treatment with a ketogenic diet (KD), which is a high-fat, low-
carbohydrate diet that mimics the metabolic state of fasting. Since
ketones use another transporter to enter the central nervous
system, they can provide the brain with an alternative source of
fuel, thereby effectively correcting the impaired brain energy
metabolism8 and reducing the frequency of the seizures and the
severity of the dystonic movement disorder.
The normal rate of cerebral oxygen consumption is low during
the fetal and perinatal periods; it then increases in a linear fashionvier Ltd. All rights reserved.
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adolescence when it shows a gradual decline.9 Therefore,
childhood is the critical period for treatment of GLUT1DS: early
diagnosis is crucial for effective KD treatment.
2. Molecular basis
GLUT1 is a member of the GLUT family of facilitative glucose
transporters, which comprises 13 proteins (gene symbol SLC2A,
protein symbol GLUT). Cloned and sequenced in 1985, GLUT1/
SLC2A1 (OMIM 138140) was the ﬁrst gene of this family to be
identiﬁed.10 Located on the short arm of chromosome 1 (1p34.2),
this gene is 35 kb long and consists of 10 exons.
GLUT1 is constitutively expressed in most tissues and
selectively expressed in erythrocytes, brain microvessels and
astroglia.3 It exists in two molecular weight forms (45 and 55 kDa),
which differ only in the extent of glycosylation of the protein.11 The
45 kDa form is detected in most cells including astrocytes and may
be responsible for basal glucose uptake by cells. The 55 kDa form is
found predominantly in the endothelial cells of brain microvessels
and erythrocytes, where it is the principal glucose transporter.6 If
there is a deﬁciency of GLUT1, the quantity of glucose passing from
the blood into the brain can be reduced, and this causes a
dysfunction in the central nervous system.
Human and animal data suggest that there is only a narrow safety
margin for glucose transport across the blood–brain barrier to meet
the needs of brain metabolism and cerebral function. A milder clinical
phenotype with intermittent symptoms (epilepsy, dyskinesias,
ataxia) may be predicted in the presence of a 25–35% reduction in
GLUT1 transporter function,12 while a more severe phenotype is
likely to result from reductions in the order of 40–75%.13
Most detected SCL2A1 mutations are de novo; in familial cases
the condition is inherited as an autosomal dominant trait with
complete penetrance. A case of autosomal recessive transmission
has also recently been described.14 All detected mutations are
heterozygous; indeed, homozygous GLUT1 mutations are presum-
ably lethal in utero.15
Patients with missense mutations generally present with
moderate to mild symptoms, but no clear-cut phenotype–genotype
correlations have been established. Indeed, patients sharing
identical mutations often do not have identical clinical manifesta-
tions, which suggests that there are additional mechanisms at work,
such as disease-modifying genes and proteins that alter phenotype
and potentially contribute to the pathophysiology of this complex
entity.16 Leen et al.8 studied 57 patients, trying to identify a speciﬁc
relationship between genotype and phenotype. They found that
mild mental retardation was more often present in patients with a
missense mutation (Type A), and movement disorders than in those
with translation initiation mutations (Type B) or multiple exon
deletions (Type C). However, severe mental retardation was found to
be present in a few Type A patients and mild mental retardation in
some Type B or C patients. Additionally, patients with the same
mutation displayed phenotypic heterogeneity, in terms of range of
clinical expression and severity. It is possible that other secondary
genes or other proteins are involved in glucose transport, which
might explain the phenotypic diversity of this disease.17
GLUT1 deﬁciency syndrome may also occur as a part of broader
genetic syndromes, as seen in microdeletion syndromes involving
the SLC2A1 gene.18
3. Clinical phenotypes
3.1. Classical phenotype
GLUT1 deﬁciency syndrome was ﬁrst described in 1991 as an
early-onset childhood epileptic encephalopathy.19 This phenotype,now deﬁned ‘‘classical’’, was rapidly expanded to include epileptic
encephalopathy with different seizure types, developmental delay,
acquired microcephaly, complex movement disorders (variable
combinations of ataxia, dystonia and spasticity), and paroxysmal
events. Seizures were initially described as brief, subtle myoclonic
limb jerking with alternating staring and eye-rolling, unrespon-
siveness, hypotonia and head bobbing. Now, also generalized
seizures of all types (absences, generalized tonic-clonic, myoclonic,
atonic, etc.) are considered features of the classical phenotype. The
movement disorders presented differ from patient to patient, but
most frequently consist of ataxia and spasticity. Paroxysmal events
of possibly non-epileptic origin include intermittent ataxia,
periodic confusion, periodic weakness, periodic limb paralysis,
recurrent headaches, and intermittent sleep disturbances.
The clinical severity of the classical phenotype varies, ranging
from mild motor and cognitive dysfunction between epileptic
attacks to severe neurological disability, with some patients never
achieving the ability to speak or walk unsupported.6 In most
patients with the classical phenotype neurological symptoms are
not inﬂuenced by fasting or food intake,20 even though there are
isolated reports of paroxysmal worsening of symptoms (mainly
movement disorders) with prolonged fasting.8
3.2. Non-classical phenotypes
Several clinical variants of GLUT1DS have been reported over
the two decades since the ﬁrst description of the classical
phenotype. Brockmann’s classiﬁcation is the one most cited in
the literature,6 and it classiﬁes patients into the following groups
on the basis of their symptoms: (i) carbohydrate-responsive
symptoms, characterized by a correlation between fasting and
neurological deterioration including seizure frequency; (ii) pre-
dominant ataxia or dystonia, but without seizures, and (iii)
paroxysmal exertion-induced dyskinesia and seizures.
However, over the years numerous atypical clinical manifesta-
tions have been described, such as paroxysmal exertion-induced
dystonia (PED) with21 or without seizures,7,22,23 choreoathetosis,24
alternating hemiplegia25 and other paroxysmal events,26 such as
intermittent ataxia, dystonia, and migraine.
At the current state of the art in understanding of GLUT1DS,
classifying the disease phenotype as ‘‘classical’’ or ‘‘non-classical’’
seems to be of limited clinical utility. It seems more appropriate to
think in terms of a broad clinical spectrum in which we can
observe:
3.2.1. Intellectual impairment
Intellectual impairment in patients with GLUT1DS varies
widely and may include: language delay, expressive language
difﬁculties possibly associated with dysarthria, learning difﬁcul-
ties, and mild, moderate or severe cognitive delay, but without a
signiﬁcant neuropsychological proﬁle. In our experience, cognitive
impairment is often proportional to the severity of other
symptoms; indeed intelligence quotient (IQ) is usually normal
in patients with minimal symptoms.
Leen et al., in their sample8 of 57 patients, found mental
retardation (from mild to severe) in almost all the patients with a
severe phenotype (46 out of 48), in half of those with a mild
phenotype (4 out of 8), and in neither of the two patients with
minimal symptoms.
Other psychiatric symptoms, such as behavioral difﬁculties,
depression, and attention deﬁcit hyperactivity disorder, are only
sporadically described.28
3.2.2. Acquired microcephaly
This is a frequent but not essential component of the clinical
spectrum.
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phenotype patients.28 Adult cases with ‘‘minimal symptoms’’ do
not present microcephaly, whereas it can be found in around 40%
of patients with mild phenotypes and in around 50% of those with a
severe phenotype (classical De Vivo syndrome).8
3.2.3. Epilepsy
GLUT1 deﬁciency syndrome should be considered in the
differential diagnosis of any form of intractable epilepsy.29 Patients
usually develop seizures in infancy and early childhood.
In infants, seizures are described as brief, subtle myoclonic limb
jerks with alternating staring and eye-rolling, sudden-onset pallor,
a dazed expression, horizontal roving eye movements, unrespon-
siveness, hypotonia and head bobbing. The EEG usually shows
multifocal spike discharges.
Pong et al.30 recently reviewed 87 patients with GLUT1DS and
noticed that 78 (90%) had epilepsy with a mean age at onset of 8
months. Seizures were a mixture of different types: generalized
tonic-clonic (53%), absence (49%), complex partial (37%), myo-
clonic (27%), drop (26%), tonic (12%), simple partial (3%), and
spasms (3%) (these authors described the ﬁrst two cases of spasms
in GLUT1DS).
In childhood, seizures are frequently myoclonic and general-
ized;28 myoclonic astatic epilepsy (MAE) is a commonly reported
form.31,32 This ﬁnding could be linked to brain maturation; indeed,
as the brain matures, seizures become synchronized and manifest
clinically as generalized events associated with 3–4 Hz spike-and-
wave discharges.
Some authors have described forms of epilepsy that are
particularly responsive to carbohydrate intake.6
However, it is important to stress that forms described as MAE
and caused by SLC2A1 mutations cannot be considered ‘‘typical’’:
GLUT1DS was present in only four out of 84 MAE probands (5%)
investigated by Mullen et al.31 and it is important to underline that
two of these patients also presented PED in childhood; another
presented ataxia, dysarthric speech and deceleration of head
growth.
Idiopathic generalized epilepsies (IGEs), not usually drug-
responsive, have also previously been described. More than 10% of
early-onset33,34 or myoclonic35 absence epilepsies are caused by
mutations of the SLC2A1 gene.
Recently, a very interesting article by Arsov et al.36 showed that
mutations of SLC2A1 are responsible for approximately 1% of all
IGEs. The authors analyzed a total of 504 probands with IGEs
(juvenile myoclonic epilepsy – 32%, juvenile absence epilepsy –
21%, childhood absence epilepsy – 31%, generalized tonic-clonic
seizures – 13%, and unspeciﬁed forms of IGE – 2%) and 470 controls.
In total, seven of the 504 probands and none of the 470 controls
had mutations demonstrating a functional effect on the protein
product. The cases described had a history of IGEs, with seizures
responding well to antiepileptic drugs (AEDs), and normal
intellectual outcome, although closer analysis of the patients’
clinical records revealed cases with atypical forms of juvenile
myoclonic epilepsy who became seizure-free on oxcarbazepine,
and cases with associated exercise-induced movement disorders.
Prior to this study, a GLUT1DS family with PED and IGEs had
already been described.37 This family showed onset of epilepsy in
adolescence/childhood but, oddly and atypically, clear and deﬁnite
EEG focus. Tzadok et al.27 recently reported a series of eight
patients with supposed IGEs but quite atypical features, namely:
absence epilepsy without myoclonias but with 3/sec spike-and-
wave discharges interspersed with polyspike waves, myoclonic
absences associated with ataxia and mild mental retardation, and
aspeciﬁc seizures with PED. A quarter of these patients with
epilepsy were found to have IGEs and the authors showed GLUT1
deﬁciency to be an important cause of IGEs.At present, GLUT1 deﬁciency should be considered the most
common known monogenic cause of atypical IGEs, and this raises
the question of whether abnormalities in glucose delivery form
part of a general, shared mechanism in IGEs.
GLUT1 deﬁciency syndrome should not really be regarded as a
clinical feature of known epileptic syndromes (myoclonus-astatic
epilepsy, absences epilepsy, etc.); rather GLUT1DS is a broad,
complex syndrome that includes seizures with speciﬁc semiology
possibly linked to known epileptic syndromes.
3.2.4. Movement disorders
Subjects with GLUT1DS commonly present complex movement
disorders, which can be characterized by ataxia, dystonia, and
chorea. These disorders can be continuous and/or paroxysmal and
can ﬂuctuate in response to different environmental stressors.8 The
most frequent stressors are fasting, infections, prolonged exercise,
and anxiety or other emotions. Pons et al.38 listed the most
frequent movement disorders in 57 GLUT1DS patients: gait
disturbances such as ataxia with/without spasticity (89%), action
limb dystonia (86%), chorea (75%), cerebellar action tremor (70%),
non-epileptic paroxysmal events (28%), dyspraxia (21%), and
myoclonus (16%).
Epilepsy and movement disorders can occur either separately
or in combination.39 Severe motor disorders, including dyskinesia,
ataxia, chorea and spasticity, associated with severe mental
retardation, have been observed in the absence of seizures.17
Paroxysmal choreoathetosis with spasticity, previously known
as dystonia type 9 (DYT9), and PED, previously known as dystonia
type 18 (DYT18), are now recognized to be part of the phenotypic
spectrum of GLUT1DS.14,22,23
Other paroxysmal events that can be observed include
weakness, lethargy, somnolence, sleep disturbances, migraines,23
writer’s cramp, parkinsonism, dyspraxia, and non-kinesigenic
dyskinesia.15,40
3.2.5. Hemolytic anemia
GLUT1 is the primary mediator of glucose transport across the
endothelium of the blood–brain barrier, into and out of astrocytes,
and into erythrocytes. However, there are rare reports of a
correlation between anemia and GLUT1: Weber et al.,23 identiﬁed a
mutation (Q282_S285del) in the pore region of GLUT1 in a family
with PED and hemolytic anemia; functional studies were
performed in erythrocytes, and the mutation was found to explain
the observed permanent cation leak responsible for the hemolytic
anemia in this family.
Flatt et al.41 suggested that two cases of stomatin-deﬁcient
cryohydrocytosis (a rare form of stomatocytosis) associated with a
cold-induced cation leak, hemolytic anemia, hepatosplenomegaly,
cataracts, seizures, mental retardation, and movement disorder,
previously reported by them, were associated with the SLC2A1
mutation Gly286Asp.
Given the rarity of such descriptions we can afﬁrm that
haploinsufﬁciency of GLUT1 is not always associated with
hemolytic anemia; this outcome depends on the type of GLUT1
mutation and whether this leads to cation leakage via the
erythrocyte membrane.42
Another extra-neurological sign we have frequently observed in
our GLUT1DS cases is prognathism: this could be a gestalt sign
worth remembering.
4. Diagnosis
4.1. Lumbar puncture
The distinctive biomarker for GLUT1DS is low CSF glucose
concentration, or hypoglycorrhachia.12
Table 1
Year Glucose Clinic
Article Total
patients
CSF mg/dl Blood/CSF
ratio
MR Seizure Motor signs Other
2003 Leary et al. 20 <40 NA + GTC, Ab, FS, MS, AS – –
2005 Klepper et al. 15 32 0.39 + + At, Dy –
2006 Friedman et al. 1 35 0.40 + FS PED, Dy, Cho, Ps –
2007 Klepper and Leiendecker 84 31 0.35  + H, At, Dy, PED, Ps –
2008 Weber et al. 4 NA 0.39–0.55 + + PED Ha
2008 Suls et al. 25 NA NA +/ Ab, GTV, FS, MS PED, Cho, Dy –
2008 Zorzi et al. 3 26–31 0.33–0.38 + + PED, Dy, Dys, AT Ps –
2009 Klepper et al. 2 36 0.44 ? ? ? ?
2010 Leen et al. 54 31–34 0.36–0.41 + + At, Dy, Cho, Ps –
2010 Mullen et al. 15 NA NA +/ Ab, FS, MAS PED –
2009 Suls et al. 4 NA NA  Ab, GTC, MS PED –
2010 Suls et al. 15 <40 NA Classical phenotipe
40–50 NA Milder phenotipe
2010 Urbizu et al. 2 NA 0.37–0.4  Ab, MS PED Wc
2011 Anheim et al. 1 40 0.50 + – At, PED W
2011 Byrne et al. 2 36 0.42–0.44  rS Ab PED, At, Cho W
2011 Fujii et al. 3 31–38 0.40–0.41 + GTC PED, At, Dys, Ps W
2011 Fung et al. 2 32–34 0.38 + MS, AA At, Dy W
2011 Gobken et al. 9 NA 0.26–0.43 +/ FS, Ab, MS Dy, At, Ps, PED –
2011 Koy et al. 1 34 0.42 + GTC PED W
2011 Hashimoto et al. 12 NA 0.28–0.48 + GTC PS AS Ab TS At, Dy –
2011 Ito et al. 6 NA 0.30–0.45 + AS, AA, MS, FS, Ab At, Dys, Ps, Dy W
2011 Mullen et al. 4 32–37 0.42 +/ MAS Tr, Dys, AT, PED –
2011 Yang et al. 71 32.31 + 4.1 0.37 + 0.08 NA NA NA NA
35.53 + 5.83 0.38 + 0.07 NA NA NA NA
2012 Afawi et al. 5 NA NA  GTC PED –
2012 Arsov et al. 7 38–49 <0.48  MS, Ab, GTC PED –
2012 Gagliardi et al. 4 NA NA + + Cho, PED –
2012 Gramer et al. 2 38–40 0.41 + MAS, GTC, AS At, PED, Dy, Dys –
2012 kitamura et al. 1 26 0.3  Ab At, PED W
2012 Pong et al. 57 NA NA + Ab GTC, CFS, MS, TS, SFS, Sp NA NA
2012 Spatola et al. NA 45 0.19–0.5 + + PED, H, At W
2012 Vieker et al. 1 34 0.39  MS, Ab, GTC – –
2013 Tzadok et al. 8 30–49 0.39–0.54 +/ GTC, MS, AA, Ab At, PED –
rS: refractory seizures; FS: focal seizures; Ab: absences; AA: atipical absences; MS: myoclonic; MAS myoclonic-astatic seizures; AS: atonic seizure, GTC: Generalized Tonic
Clonic; TS Tonic Seizure. MR: mental retardation. H: Hypotonia; At: ataxia; Dys: dysarthia; Dy: dystonia; Cho: chorea, Ps: piramidal signs, Tr: tremor. W: weakness, M:
migraine; Wc: Writer’s cramp; Ha: Hemolytic Anemia.
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conditions, such as prolonged seizures/status epilepticus, mito-
chondrial diseases, infectious meningitis, hypoglycemic states,
subarachnoid hemorrhage, and meningeal carcinomatosis.43,44 If
these conditions are ruled out, the presence of hypoglycorrhachia
strongly indicates GLUT1DS.
The CSF-to-blood glucose ratio is superior to the absolute
glucose level in CSF. Normal CSF-to-blood glucose ratios are above
0.6.
Initially, a CSF-to-blood glucose ratio of 0.33–0.37 (CSF
concentration 40 mg/dl)18 was set as the cut-off value for a
diagnosis of GLUT1DS in suspected cases. However, with the
increasing recognition of milder allelic variants, higher values are
now being applied (see Table 1).
However, this aspect continues to be debated in the literature;
Suls et al.,22,34 Mullen et al.,31 Weber et al.23 and our own
experience suggest that milder phenotypes, especially ones
characterized by movement disorders without epilepsy, can be
associated with ratios of up to 0.59 (CSF glucose 60 mg/dl), even
though, as afﬁrmed by De Vivo and Wang45 and Yang et al.,13 in the
vast majority of cases (>90%) values are lower than 0.37. Several
attempts have been made to correlate clinical severity with the
degree of hypoglycorrhachia,8 but conclusive results are still
lacking.
These observations indicate that the normal range for CSF
glucose has never been deﬁned properly. The risk that some
patients with normal glycorrhachia might even go undiagnosed
and untreated suggests that molecular analysis of the SLC2A1 geneshould be used as an alternative gold standard for diagnosing
GLUT1DS, when the condition is strongly suspected.29
On the other hand, Klepper and Leiendecker reported that about
30% of patients in their cohort of 84 patients with hypoglycor-
rhachia5 did not carry mutations, which suggests the existence of
alternative disease mechanisms. In these patients with highly
suggestive clinical ﬁndings and low CSF glucose, treatment with
KD should always be attempted.
Lumbar puncture should be performed in the fasting state, and
the blood sample used for measurement of glucose concentration
should be obtained immediately before the lumbar puncture to
avoid stress-related hyperglycemia.
Reduced lactate concentration (below 1.4 mmol/l)19,20 could be
another CSF marker of GLUT1DS, although in our personal
experience we have not found lactate levels in GLUT1DS to be
signiﬁcantly lower than normal (mean value 1.6 mmol/l). Klep-
per29 recently afﬁrmed that CSF lactate is never elevated in
GLUT1DS.
4.2. Erythrocyte 3-OMG uptake
As the GLUT1 gene is also expressed in erythrocytes, the ﬁnding
of decreased uptake of 3-O-methylglucose (3-OMG) into erythro-
cytes could also serve to conﬁrm a diagnosis of GLUT1DS.
Pathogenic mutations cause haploinsufﬁciency, and therefore
decrease 3-OMG uptake by approximately 50%.19 However, the
phenotype associated with the T295M mutation in SLC2A1
shows normal 3-OMG uptake in erythrocytes, and thus leads to
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Furthermore, these investigations are not commercially available and
are demanding in terms of protocol, time, sample size and sample
quality.29
4.3. Molecular analysis
Approximately 70–80% of patients carry SLC2A1 mutations.15
Genetic testing is commercially available worldwide. It should
include polymerase chain reaction (PCR) sequencing of all 10
exons, splice site, and the promoter region.7 If it is negative,
deletions/duplications within the SCL2A1 gene can be detected by
multiplex ligation-dependent probe ampliﬁcation (MLPA).8
In SCL2A1-negative patients, GLUT1DS can be diagnosed only in
the presence of clear hypoglycorrhachia. In such cases it is, indeed,
reasonable to suspect GLUT1DS and to initiate KD treatment. An
immediate response to the diet will support the diagnosis.29
These patients constitute a particularly interesting subset as
they might carry defects in GLUT1 assembly, three-dimensional
GLUT1 folding, GLUT1 trafﬁcking to the cell, or GLUT1 activation.5
5. EEG ﬁndings
No characteristic electroencephalography (EEG) pattern in
GLUT1DS has yet been identiﬁed, and patients can actually show
a normal interictal EEG.6,30
Infants with GLUT1DS can present with multifocal spike
discharges on EEG, underlying infantile focal seizures (non-
generalized) that may include eye movements, cyanotic spells,
etc.46 Subsequently, as the brain matures, these seizures become
synchronized and clinically manifest themselves as generalized
events associated with 3–4 Hz spike-and-wave discharges.
Tzadoket al.27 maintain that the presence of polyspike wave
discharges in the context of absence epilepsy without myoclonus
or prominent aggravation of generalized polyspike wave dis-
charges during sleep – which they did not usually observe in IGE
patients – could be characteristic signs.
However, on the basis of our personal experience, we suggest
that the above-mentioned features can also be present in ‘‘simple’’
forms of IGE. In our sample of GLUT1DS patients (article in press),
we found that many ‘‘unusual’’ signs can be detected in idiopathic
forms, such as the presence of atypical spike-and-wave discharges.
In our view, these ﬁndings cannot be taken as characteristic signs.
On the contrary, some authors have reported improvement in
the EEG ﬁndings post-prandially or after intravenous administra-
tion of glucose.47 These EEG recordings could offer a simple
screening test for GLUT1DS, even though, on their own, they
cannot be considered diagnostic.
Marin-Valencia et al.48 recently demonstrated in a mouse
model of GLUT1DS that thalamocortical hypersynchronization is
an important mechanism in GLUT1DS epileptogenesis due to
impaired glucose uptake. Intrinsic cortical hyperexcitability arises
from failure of internal thalamic inhibition, which causes
propagation of excitation to the cortex; this could explain the
frequent clinical presentation of absence epilepsy in patients with
GLUT1DS. Moreover, because brain cells derive most of their
energy from glucose, GLUT1 deﬁciency also impairs the synthesis
of key molecules involved in energy production and neurotrans-
mission, such as acetyl-CoA, tricarboxylic acid cycle intermediates
and other derivatives.
6. Brain imaging
Neuroimaging ﬁndings in patients with GLUT1DS are not
signiﬁcant. Magnetic resonance imaging (MRI) scans of patientswith GLUT1DS mostly show either normal ﬁndings6 or occasion-
ally mild enlargement of inner and outer CSF spaces.5,49
Cerebral ﬂuorodeoxyglucose positron emission tomography
(PET) in 14 patients with the classical GLUT1DS phenotype
revealed a global decrease in glucose uptake in the cortex, more
severe in the mesial temporal regions and thalami, and less marked
in the basal ganglia.22 The distinctive PET signature appears in
early infancy and persists into adulthood regardless of disease
severity or KD therapy. Although PET is readily available in clinical
practice, the sensitivity and speciﬁcity of PET in the diagnosis of
GLUT1DS have not yet been established.50
7. Treatments
7.1. Ketogenic diet
In the fasting state, brain glycogen storage is exhausted within
minutes. The brain cannot utilize amino acids and fat to produce
energy and, in the absence of glycogen, switches to ketones as an
alternative fuel to maintain function. Ketones are generated in the
liver from fatty acid degradation and enter the brain via facilitated
diffusion mediated by the monocarboxylate transporter 1 (MCT1
transporter). This mechanism is particularly effective in infants
and young children in whom ketone extraction and utilization is
three-to-four-fold higher than in adults.2
The KD is a high-fat, carbohydrate-restricted diet that mimics
the metabolic state of fasting. It has been used safely and
effectively for decades in intractable childhood epilepsy.1 The
classic KD, as developed by the Johns Hopkins University, uses
long-chain triglycerides and consists of 4 g of fat to every 1 g of
carbohydrate and protein combined (4:1 ratio) with supplemental
vitamins and minerals. The spectrum of the KD has now increased
considerably51 and includes several alternative diets such as the
classic KD with a 3:1 ratio, medium-chain triglycerides (MCTs), the
modiﬁed Atkins diet (MAD) (which provides 10 g carbohydrates/
day in children and 15 g/day in adults), and the low glycemic index
treatment (LGIT), which restricts the consumption of certain types
of carbohydrate-containing foods.
Novel indications for KD include disorders of brain energy
metabolism such as pyruvate dehydrogenase deﬁciency (PDHP)
and GLUT1DS.52
Although, in epilepsy, the mechanism of action underlying the
effectiveness of the KD is not yet clear,53 in GLUT1DS it essentially
provides an alternative fuel source. The effectiveness of the KD in
GLUT1DS might be enhanced by its anticonvulsant action. The vast
majority of GLUT1DS patients obtain seizure freedom with the
classical 4:1 or 3:1 formula, allowing anticonvulsant therapy to be
withdrawn.5 There are a few reports in which the KD was not fully
effective and anticonvulsants were not completely eliminated.54,55
The KD also has a positive effect on movement disorders such as
hypotonia, ataxia, dystonia, and PED.24,56
The impact of KD treatment on developmental delay appears
less prominent.6 However, several authors have reported a marked
increase in alertness and activity in patients on the KD.
Our own experience has shown that introduction of the KD in
the ﬁrst years of life in patients with GLUT1DS guarantees a better
cognitive outcome. The literature contains numerous reports of
improved psychomotor impairment, but these are hard to verify in
case–control studies.
As the developing brain in the young child requires more
energy, the KD should be started as early as possible whenever
GLUT1DS is suspected. There are also reports of voluntary intake of
large amounts of fat-containing food in patients subsequently
diagnosed as GLUT1DS.57
It remains unclear whether a rigorous KD is essential in
GLUT1DS. Seizure and movement disorder control can be achieved
V. De Giorgis, P. Veggiotti / Seizure 22 (2013) 803–811808by a 2:1 or 3:1 ketogenic ratio but the relationship between ketosis
and neurodevelopmental outcome remains undetermined. The
MAD is also well tolerated and provides effective symptom
control; furthermore, this diet has the advantage of being easy to
prepare and more palatable, which are important requirements forGLUT1DS  s
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our practice to use only MCTs in our drug-resistant epilepsy or
GLUT1DS patients.
Fig. 1 details, in addition to the diagnostic procedure, our
clinical practice as regards the use of the KD in GLUT1DS patients at
different ages and in different classes of severity.
There remain various challenges to be addressed. These include
determination of the most efﬁcient ratio and composition of the
diets, and the development of treatment strategies in GLUT1DS
adults.
The KD approach has advanced considerably over the past
years, to the point that it is now considered a ﬁrst-line therapy in
infantile spasms, MAE, Dravet syndrome, and status epilepticus
[including febrile infection-related epilepsy syndrome]. KDs are
also now being increasingly studied for neurological conditions
other than epilepsy, including Alzheimer’s disease and cancer.53
Further research could shed light on the mechanisms that may
make metabolism-based therapy particularly helpful in terms of
anticonvulsant and possibly neuroprotective effects.
7.2. Additional measures
Treatment with a KD should be complemented by additional
measures: pharmacological agents known to impair GLUT1
function, e.g. caffeine, phenobarbital, diazepam, chloral hydrate
and tricyclic antidepressants, should be avoided.49
There are also reports of the use of alternative compounds for
the treatment of GLUT1DS.
Alpha lipoic acid is an antioxidant that serves as a co-enzyme in
energy metabolism. It neutralizes free radicals, improves cellular
glucose uptake by stimulating the insulin signal cascade, reduces
inﬂammation, and binds with metals. Alpha lipoic acid supple-
mentation has been recommended in GLUT1DS on the basis of the
observation that it improves glucose transport in cultured muscle
cells via mobilization of the GLUT4 transporter from intracellular
pools;20,30 however, to date there are no published data in humans
to demonstrate its effectiveness.
Acetazolamide was reported to be beneﬁcial for paroxysmal
dyskinesias in a single patient with GLUT1DS.58
Triheptanoin is a triglyceride that has been used as an
anaplerotic substrate in humans to treat inherited metabolic
diseases such as pyruvate carboxylase deﬁciency and carnitine
palmitoiyltransferase II deﬁciency.59 It is metabolized into ﬁve
carbon compounds that easily cross the blood–brain barrier via
monocarboxylate transporters and may enhance the effect of the
regular ketones as an alternative fuel for the brain. Although
promising in theory, there are currently no clinical data to support
the use of this compound in GLUT1DS.
8. Follow-up and outcome
Regular follow-up visits are needed after a diagnosis of
GLUT1DS in order to monitor the patient’s clinical evolution.
Patients starting KD treatment should be monitored particu-
larly closely.
In accordance with the 2011 Italian consensus statement on KD
therapy,39 we recommend that follow-up of GLUT1DS children/
adults include regular dietary and neurological evaluations and
EEG, performed at least ﬁve times in the ﬁrst year of treatment
(after 1, 3, 6, 9, and 12 months). Annual cognitive and
developmental assessments are also recommended, as are regular
blood and metabolic evaluations.
In contrast to intractable childhood epilepsy patients, individ-
uals affected by GLUT1DS should continue the diet into adoles-
cence to meet the increased energy demands of the developing
brain.52 In our opinion, KD treatment can be useful in adulthood,too, because even though epilepsy seems to disappear in
adulthood, the movement disorder can persist unchanged and
there are, as yet, no reliable data conﬁrming a stable cognitive
outcome in adult patients with GLUT1DS. More important, the KD
might exert neuroprotective effects. Low glucose concentrations in
the CSF can lead to oxidative DNA damage and lipid peroxidation.
Chronic ketosis limits the generation of reactive oxygen species
and boosts energy reserve capacity, which is important in
sustaining the electrophysiological activities essential for perform-
ing brain function.60 Furthermore, in GLUT1DS patients, KD
therapy could be beneﬁcial to organs expressing GLUT1 at high
levels such as the retina, colon, ovaries and testicles.1
For these reasons, if there are no serious side effects, we
recommend lifelong KD treatment in GLUT1DS patients, even if
symptom control is not complete. It is necessary to compensate for the
deﬁcit caused by the failure of glucose to cross the blood–brain barrier
in order to reduce the long-term risks associated with the disease.
In our experience, compliance is much better in GLUT1DS than
in the other conditions for which KD treatment is indicated.
According to the literature there is a good level of satisfaction: up
to 75% of patients consider the diet effective and 50% tolerate and
accept it.55
The question of when to discontinue AEDs in patients with
GLUT1DS is not really debated in the literature. According to our
protocol, if seizures and non-epileptic paroxysmal events have
disappeared, gradual reduction of AEDs can start from the ﬁrst year
after the introduction of the KD. If the diet does not completely
control the symptoms, AEDs are continued at the most effective
and best tolerated dose.
No information is available on the long-term efﬁcacy and
tolerability of the treatment in GLUT1DS patients, but non-
GLUT1DS seizure-free epileptic patients on the diet for >10 years
have been reported.61
9. Conclusions
GLUT1 deﬁciency syndrome results from impaired glucose
transport into the brain. Recently the clinical spectrum of GLUT1DS
has been broadened and it is becoming less meaningful to consider
the disease in terms of ‘‘classical’’ and ‘‘non-classical’’ phenotypes.
On the basis of current knowledge, this disease should be
suspected (Fig. 1) and a CSF investigation (with determination of
the CSF-to-blood glucose ratio) strongly recommended in the
presence of:
- any seizures that are refractory and/or inﬂuenced by fasting,
especially if associated with mild neurological (pyramidal or
extra-pyramidal) signs and/or mental impairment and/or atypi-
cal EEG features and/or a family history of epilepsy or movement
disorder.
- any history of unexplained paroxysmal events – especially if PED
– associated with previous self-limited seizures and/or mental
impairment and/or a family history of epilepsy or movement
disorder.
Other signs such as microcephaly, mental retardation, and
dysarthria are frequently observed in GLUT1DS patients, however
our experience shows that they are not hallmarks.
An extra-neurological sign we frequently observed in our
GLUT1DS cases was prognathism: this could be a gestalt sign worth
remembering.
The question of whether or not to perform lumbar puncture has
been extensively debated in the literature. Even today, most
patients presenting with epilepsy or a movement disorder do not
have a diagnostic lumbar puncture.
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continuing value of the lumbar puncture as the classical approach to
the neurological patient with an unexplained condition. This
procedure has withstood the test of time and remains cost-efﬁcient.
It is true that gene sequencing is an increasingly available, non-
invasive test with a pretest probability of 1% for IGEs,36 rising to 10%
for early-onset absence epilepsy.31 However, we do not consider it
useful to perform mutational analysis of the SLC2A1 gene in all
patients with early-onset absence epilepsies or epilepsy with
myoclonic-atonic seizures,62 believing, instead, that the analysis
should be reserved for patients with highly suggestive clinical
ﬁndings and low CSF glucose or borderline clinical ﬁndings and CSF
glucose who require genetic testing to conﬁrm the diagnosis prior to
starting a KD. This approach is certainly less expensive than wider
genetic screening, and also feasible worldwide.
At present, it seems most interesting to focus on those patients
who have a clinical picture highly suggestive of GLUT1DS, a low
glycorrhachia value, and possibly a good response to the KD, but
who are negative on gene SLC2A1 sequencing and MLPA. In these
SLC2A1-negative GLUT1DS patients other potential disease mech-
anisms could be at work.63
This is why sequencing of the entire exome should be
performed in an attempt to identify other genes possibly
implicated in GLUT1 protein assembly, three-dimensional folding,
trafﬁcking to the cell, or activation.
It is essential diagnose this entity as early as possible to allow
prompt compensation, through the KD, for the brain’s lack of fuel.
Early identiﬁcation of children with GLUT1DS is important in order
to avoid submitting them to possibly ineffective or potentially
detrimental treatments with anticonvulsants, and to ensure that
their brains are provided with an alternative energy source during
a time of increased cerebral metabolism.
On the basis of current knowledge, it is not possible to say with
absolute certainty that the condition of GLUT1DS patients never
deteriorates. The hallmark deﬁciency of glucose in the CNS, if
allowed to persist for many years, could be responsible for brain
atrophy, which could be observed on the MRI scans of these
patients, and for a moderate but steady reduction of IQ, as well as
for the maintenance of more or less drug-resistant epilepsy and a
disabling movement disorder. The few GLUT1DS adult patients
identiﬁed to date do not provide sufﬁcient evidence to clarify our
doubts in this regard.
Ongoing research to discover pathogenic mechanisms under-
lying different phenotypes, the availability of new animal models
of GLUT1DS, growing patient numbers, and the diffusion of
knowledge of this relatively ‘‘new’’ disease could help us to provide
answers to some of the many still open questions about GLUT1DS.
Moreover exomewide sequencing in a small number of patients
with a similar phenotype could disclose other genes implicated in
GLUT1DS.
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